Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Amyloidosis in Transthyretin (TTR)

Tundra lists 3 Amyloidosis in Transthyretin (TTR) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07213297

Comprehensive Program for Hereditary Transthyretin Amyloidosis

The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis (ATTR), a progressive and potentially fatal condition marked by amyloid fibril deposits impacting multiple organs. The trial aims to characterize patient phenotypes, investigate factors affecting disease progression, and identify minimum criteria for disease onset. Conducted at Néstor Kirchner Hospital, the trial enrolls participants over 18 years old with confirmed pathogenic TTR variants. It includes thorough evaluations such as genetic testing sponsored by pharmaceutical companies, clinical assessments, and diverse diagnostic tests.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-24

1 state

Amyloidosis in Transthyretin (TTR)
Amyloidosis, Familial
NOT YET RECRUITING

NCT07116473

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).

Gender: All

Ages: 18 Years - Any

Updated: 2025-08-11

Amyloidosis in Transthyretin (TTR)
Amyloidosis, Familial
Amyloid Cardiomyopathy
+7
ACTIVE NOT RECRUITING

NCT07080268

Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.

Prospective study of development and validation of a questionnaire on quality of life in patients with Hereditary Amyloidosis The questionnaire development process will include 4 medical specialists experts in Transthyretin Amyloidosis (2 neurologists, 1 cardiologist, 1 physician clinical/hepathologist), 1 psychologist; 1 social worker; and 3 patients (with confirmed Hereditary amyloidosis) members of ALAPA. (Local PAG) Population and sample:

Gender: All

Ages: 18 Years - Any

Updated: 2025-07-23

1 state

Amyloidosis in Transthyretin (TTR)
Hereditary Amyloidosis, Transthyretin-Related